No products in the cart.
Pre-made Refanezumab benchmark antibody ( Whole mAb, anti-MAG therapeutic antibody, Anti-GMA/S-MAG/SIGLEC-4A/SIGLEC4A/SPG75 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-474
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Refanezumab biosimilar, Whole mAb, Anti-MAG Antibody: Anti-GMA/S-MAG/SIGLEC-4A/SIGLEC4A/SPG75 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Refanezumab (GSK249320) is a monoclonal antibody designed for the recovery of motor function after stroke.
| Products Name (INN Index) | Pre-Made Refanezumab biosimilar, Whole mAb, Anti-MAG Antibody: Anti-GMA/S-MAG/SIGLEC-4A/SIGLEC4A/SPG75 therapeutic antibody |
|---|---|
| INN Name | Refanezumab |
| Target | MAG |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | GlaxoSmithKline |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | CNS trauma,Stroke |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MAG |
| Package |
Previous slide
Next slide
